BMAA neurotoxicity in Drosophila

Amyotrophic Lateral Sclerosis

Volumn 10, Issue SUPPL. 2, 2009, Pages 61-66

  Zhou, Xianchong ^a   Escala, Wilfredo ^b   Papapetropoulos, Spyridon ^a   Bradley, Walter G ^a   Zhai, R Grace ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

ALS; Drosophila; Neurodegeneration

Indexed keywords

2 AMINO 3 METHYLAMINOPROPIONIC ACID;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIFESPAN; MALE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

ALANINE; AMINO ACIDS, DIAMINO; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DROSOPHILA MELANOGASTER; FEMALE; GLUTAMIC ACID; LEUCINE; LONGEVITY; LYSINE; MALE; NEUROTOXICITY SYNDROMES; NEUROTOXINS;

EID: 74549115178     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482960903273445     Document Type: Conference Paper

References (25)

1. Cox PA , Sacks OW. Cycad neurotoxins, consumption of flying foxes, and ALS/PDC disease in Guam. Neurology. 2002; 58:956-9.
2. Cox PA, Banack SA, Murch SJ. Biomagnifi cation of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc Natl Acad Sci USA. 2003;100:13380-3.
3. Banack SA, Johnson HE, Cheng R, Cox PA . Production of the neurotoxin BMAA by a marine cyanobacterium. Marine Drugs. 2007;5:180-96.
4. Metcalf JS, Banack SA, Lindsay J, Morrison LF, Cox PA, Codd GA. Co-occurrence of beta-N-methylamino-L-alanine, a neurotoxic amino acid with other cyanobacterial toxins in British waterbodies, 1990-2004. Environ Microbiol. 2008; 10:702-8.
5. Johnson HE, King SR, Banack SA, Webster C, Callanaupa WJ, Cox PA. Cyanobacteria (Nostoc commune) used as a dietary item in the Peruvian highlands produce the neurotoxic amino acid BMAA. J Ethnopharmacol. 2008; 118:159-65.
6. Papapetropoulos S. Is there a role for naturally occurring cyanobacterial toxins in neurodegeneration? The beta-N-methylamino-L-alanine (BMAA) paradigm. Neurochem Int. 2007;50:998-1003.
7. Mash DC. Cyanobacterial toxins in neurodegeneration. Continuum: Lifelong Learning. Neurol. 2008;14:138-49.
8. Murch SJ, Cox PA , Banack SA, Steele JC, Sacks OW. Occurrence of beta-methylamino-l-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol Scand. 2004; 110:267-9.
9. Murch SJ, Cox PA, Banack SA. A mechanism for slow release of biomagnifi ed cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proc Natl Acad Sci USA. 2004;101:12228-31.
10. Lobner D, Piana PM, Salous AK, Peoples RW. Beta-N-methylamino-L-alanine enhances neurotoxicity through multiple mechanisms. Neurobiol Dis. 2007;25:360-6.
11. Rao SD, Banack SA, Cox PA , Weiss JH. BMAA selectively injures motor neurons via AMPA/kainate receptor activation. Exp Neurol. 2006;201:244-52.
12. Brownson DM, Mabry TJ, Leslie SW. The cycad neurotoxic amino acid, beta-N-methylamino-L-alanine (BMAA), elevates intracellular calcium levels in dissociated rat brain cells. J Ethnopharmacol. 2002;82:159-67.
13. Watson MR, Lagow RD, Xu K, Zhang B, Bonini NM. A Drosophila model for amyotrophic lateral sclerosis reveals motor neuron damage by human SOD1. J Biol Chem. 2008;283:24972-81.
14. Tsuda H, Han SM, Yang Y, Tong C, Lin YQ, Mohan K, et al. The amyotrophic lateral sclerosis 8 protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors. Cell. 2008;133:963-77.
15. Ratnaparkhi A, Lawless GM, Schweizer FE, Golshani P, Jackson GR. A Drosophila model of ALS: human ALS-associated mutation in VAP33A suggests a dominant negative mechanism. PLoS ONE. 2008;3:2334.
16. Sang TK, Jackson GR. Drosophila models of neurodegenerative disease. NeuroRx. 2005;2:438-46.
17. Benzer S. From the gene to behavior. JAMA. 1971;218:1015- 22.
18. Benzer S. Genetic dissection of behavior. Sci Am. 1973; 229:24-37.
19. Hotta Y, Benzer S. Mapping of behavior in Drosophila mosaics. Symp Soc Dev Biol. 1973;31:129-67.
20. Le Bourg E, Lints FA. Hypergravity and aging in Drosophila melanogaster. 4. Climbing activity. Gerontology. 1992;38: 59-64.
21. Ganetzky B, Flanagan JR. On the relationship between senescence and age-related changes in two wild-type strains of Drosophila melanogaster. Exp Gerontol. 1978; 13:189-96.
22. Trotti D. A role for glutamate transporters in neurodegenerative diseases. Adv Exp Med Biol. 2002;513:225-48.
23. Billups B, Rossi D, Oshima T, Warr O, Takahashi M, Sarantis M, et al. Physiological and pathological operation of glutamate transporters. Prog Brain Res. 1998;116:45-57.
24. Smith QR, Nagura H, Takada Y, Duncan MW. Facilitated transport of the neurotoxin, beta-N-methylamino-L-alanine, across the blood-brain barrier. J Neurochem. 1992; 58:1330-7.
25. Duncan MW, Villacreses NE, Pearson PG, Wyatt L, Rapoport SI, Kopin IJ, et al. 2-amino-3-(methylamino)-propanoic acid (BMAA) pharmacokinetics and blood-brain barrier permeability in the rat. J Pharmacol Exp Ther. 1991;258:27-35.